<SEC-DOCUMENT>0001193125-20-182326.txt : 20200629
<SEC-HEADER>0001193125-20-182326.hdr.sgml : 20200629
<ACCEPTANCE-DATETIME>20200629160631
ACCESSION NUMBER:		0001193125-20-182326
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20200623
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200629
DATE AS OF CHANGE:		20200629

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACADIA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001070494
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				061376651
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50768
		FILM NUMBER:		20997542

	BUSINESS ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DRIVE
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-558-2871

	MAIL ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DRIVE
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d23206d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:acad="http://www.acadia-pharm.com/20200623" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2020-06-23_to_2020-06-23">ACADIA PHARMACEUTICALS INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2020-06-23_to_2020-06-23">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2020-06-23_to_2020-06-23">0001070494</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="acad-20200623.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2020-06-23_to_2020-06-23"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001070494</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-06-23</xbrli:startDate> <xbrli:endDate>2020-06-23</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="font-size:10pt;width:8.5in;margin:0 auto"> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:0pt">&#160;</p></div> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:2pt">&#160;</p></div> <p style="margin-bottom:0px;margin-top:4pt"></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0pt;margin-top:0pt">UNITED STATES</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0pt;margin-top:0pt">SECURITIES AND EXCHANGE COMMISSION</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">WASHINGTON, D.C. 20549</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0px;margin-top:12pt">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2020-06-23_to_2020-06-23">8-K</ix:nonNumeric></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:12pt">CURRENT REPORT</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">Pursuant to Section 13 or 15(d)</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">of the Securities Exchange Act of 1934</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:12pt">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2020-06-23_to_2020-06-23" format="ixt:datemonthdayyearen">June 23, 2020</ix:nonNumeric></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:24pt;margin-bottom:0px;margin-top:12pt"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">ACADIA Pharmaceuticals Inc.</span> </p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">(Exact name of registrant as specified in its charter)</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2020-06-23_to_2020-06-23" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2020-06-23_to_2020-06-23">000-50768</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2020-06-23_to_2020-06-23">06-1376651</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(State or other jurisdiction of</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">incorporation or organization)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Commission</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">File Number)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(IRS Employer</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Identification No.)</p></td></tr></table>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:50%;"></td>
<td style="width:1%;"></td>
<td style="width:48%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2020-06-23_to_2020-06-23">3611 Valley Centre Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2020-06-23_to_2020-06-23">Suite 300</ix:nonNumeric></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2020-06-23_to_2020-06-23">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2020-06-23_to_2020-06-23" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2020-06-23_to_2020-06-23">92130</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Address of principal executive offices)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Zip Code)</p></td></tr></table> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:12pt">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2020-06-23_to_2020-06-23">(858)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2020-06-23_to_2020-06-23">558-2871</ix:nonNumeric></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:12pt">N/A</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Former name or former address, if changed since last report.)</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form 8-K):</p> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2020-06-23_to_2020-06-23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2020-06-23_to_2020-06-23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2020-06-23_to_2020-06-23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2020-06-23_to_2020-06-23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr></table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Securities registered pursuant to Section 12(b) of the Act:</p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="border-bottom:1pt solid #000000;white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Title of each class</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Trading</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Symbol(s)</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Name of each exchange</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">on which registered</p></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2020-06-23_to_2020-06-23">Common Stock, par value $0.0001 per share</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2020-06-23_to_2020-06-23">ACAD</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2020-06-23_to_2020-06-23" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td></tr></table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#32;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p> <p style="font-family:Times New Roman;margin-left:0%;text-align:left;text-indent:0%;font-size:10pt;margin-bottom:0px;margin-top:12pt">Emerging growth company&#160;&#160;<span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2020-06-23_to_2020-06-23" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;<span style="font-family:Times New Roman;font-weight:normal">&#9744;</span></p> <p style="margin-bottom:0px;margin-top:10pt"></p> <div style="text-align:center"> <p style="line-height:0.5pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:0pt">&#160;</p></div> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:2pt">&#160;</p></div> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto">
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;5.02 </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</td> </tr> </table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;text-align:left;">&#160;</td>
<td style="width:4%;vertical-align:top;">(e) </td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">On June&#160;23, 2020, the stockholders of ACADIA Pharmaceuticals Inc. (the &#8220;Company&#8221;) approved an amendment to the Company&#8217;s 2004 Employee Stock Purchase Plan, as amended (the &#8220;2004 ESPP&#8221;), to increase the aggregate number of shares of common stock authorized for issuance under the plan by 3,000,000 shares.</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The foregoing description of the 2004 ESPP does not purport to be complete, and is qualified in its entirety by reference to Exhibit 99.1 to this Report, as well as the description of the 2004 ESPP included in the Company&#8217;s definitive proxy statement filed with the Securities and Exchange Commission on April&#160;29, 2020 (the &#8220;proxy statement&#8221;). </p> <p style="margin-bottom:0px;margin-top:18pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;5.07 </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Submission of Matters to a Vote of Security Holders.</td> </tr> </table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;text-align:left;">&#160;</td>
<td style="width:4%;vertical-align:top;">(a) </td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The Company held its 2020 Annual Meeting of Stockholders on June&#160;23, 2020 (the &#8220;2020 Annual Meeting&#8221;).</td> </tr> </table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;text-align:left;">&#160;</td>
<td style="width:4%;vertical-align:top;">(b) </td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The election of two nominees to serve as Class&#160;I directors on the Company&#8217;s Board of Directors until the Company&#8217;s 2023 Annual Meeting of Stockholders was carried out at the 2020 Annual Meeting. The following two Class&#160;I directors were elected by the votes indicated:</td> </tr> </table>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:84%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:63%;"></td>
<td style="width:3%;"></td>
<td></td>
<td></td>
<td></td>
<td style="width:3%;"></td>
<td></td>
<td></td>
<td></td>
<td style="width:3%;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="white-space:nowrap;vertical-align:bottom;text-align:left;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:8pt;margin-bottom:0pt;margin-top:0pt;border-bottom:1pt solid #000000;display:inline-block"></p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">For </p> </td>
<td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:bottom;">&#160;</td>
<td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Withheld </p> </td>
<td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:bottom;">&#160;</td>
<td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Broker Non- <br />Votes </p> </td>
<td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td> </tr>
<tr style="background-color:#cceeff;page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:1.00em;text-align:left;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">James M. Daly </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:bottom;text-align:right"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">108,687,443 </p> </td>
<td style="vertical-align:bottom;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:bottom;text-align:right"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">25,123,699 </p> </td>
<td style="vertical-align:bottom;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:bottom;text-align:right"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">12,812,216 </p> </td>
<td style="vertical-align:bottom;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:1.00em;text-align:left;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Edmund P. Harrigan, M.D. </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:bottom;text-align:right"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">132,613,336 </p> </td>
<td style="vertical-align:bottom;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:bottom;text-align:right"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">1,197,806 </p> </td>
<td style="vertical-align:bottom;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:bottom;text-align:right"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">12,812,216 </p> </td>
<td style="vertical-align:bottom;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">In addition to the election of two Class&#160;I directors, the following matters were submitted to a vote of the stockholders at the 2020 Annual Meeting: </p> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;text-align:left;">&#160;</td>
<td style="width:4%;vertical-align:top;">(i) </td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the approval of an amendment to the 2004 ESPP increasing the aggregate number of shares of common stock authorized for issuance under the plan by 3,000,000 shares, which was approved by the following vote:</td> </tr> </table>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:86%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:24%;"></td>
<td></td>
<td style="width:23%;"></td>
<td style="width:1%;"></td>
<td style="width:24%;"></td>
<td style="width:1%;"></td>
<td style="width:23%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="border-bottom:1pt solid #000000;white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">For </p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Against </p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Abstain </p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Broker <span style="white-space:nowrap">Non-Votes </span></p> </td> </tr>
<tr style="background-color:#cceeff;page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:1.00em;text-align:center;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">132,878,639 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;margin-left:1.00em;text-align:center;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">832,420 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;margin-left:1.00em;text-align:center;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">100,083 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;margin-left:1.00em;text-align:center;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">12,812,216 </p> </td> </tr> </table> <p style="margin-bottom:0px;margin-top:12pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;text-align:left;">&#160;</td>
<td style="width:4%;vertical-align:top;">(ii) </td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the approval of the Company&#8217;s <span style="white-space:nowrap">non-employee</span> director compensation policy, a copy of which is attached as Exhibit 99.2 to this Report, which was approved by the following vote:</td> </tr> </table>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:92%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:24%;"></td>
<td></td>
<td style="width:23%;"></td>
<td style="width:1%;"></td>
<td style="width:24%;"></td>
<td style="width:1%;"></td>
<td style="width:23%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="border-bottom:1pt solid #000000;white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">For </p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Against </p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Abstain </p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Broker<span style="white-space:nowrap">&#160;Non-Votes</span></p> </td> </tr>
<tr style="background-color:#cceeff;page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:1.00em;text-align:center;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">128,021,969 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;margin-left:1.00em;text-align:center;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">5,645,500 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;margin-left:1.00em;text-align:center;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">143,673 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;margin-left:1.00em;text-align:center;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">12,812,216 </p> </td> </tr> </table> <p style="margin-bottom:0px;margin-top:12pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;text-align:left;">&#160;</td>
<td style="width:4%;vertical-align:top;">(iii) </td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the approval, on an advisory basis, of the compensation of the Company&#8217;s named executive officers, as disclosed in the proxy statement, which was approved by the following vote:</td> </tr> </table>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:92%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:24%;"></td>
<td></td>
<td style="width:23%;"></td>
<td style="width:1%;"></td>
<td style="width:24%;"></td>
<td style="width:1%;"></td>
<td style="width:23%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="border-bottom:1pt solid #000000;white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">For </p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Against </p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Abstain </p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Broker <span style="white-space:nowrap">Non-Votes </span></p> </td> </tr>
<tr style="background-color:#cceeff;page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:1.00em;text-align:center;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">127,535,500 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;margin-left:1.00em;text-align:center;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">6,110,192 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;margin-left:1.00em;text-align:center;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">165,450 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;margin-left:1.00em;text-align:center;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">12,812,216 </p> </td> </tr> </table> <p style="margin-bottom:0px;margin-top:12pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;text-align:left;">&#160;</td>
<td style="width:4%;vertical-align:top;">(iv) </td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the appointment of Ernst&#160;&#038; Young LLP as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2020 was ratified by the following vote:</td> </tr> </table>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:88%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="border-bottom:1pt solid #000000;white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">For </p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Against </p> </td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Abstain </p> </td> </tr>
<tr style="background-color:#cceeff;page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:1.00em;text-align:center;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">146,289,506 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">138,089 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">195,763 </p> </td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Each of the foregoing voting results from the 2020 Annual Meeting is final. </p> <p style="margin-bottom:0px;margin-top:18pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;9.01 </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Financial Statements and Exhibits.</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">(d) Exhibits </p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td></td>
<td></td>
<td></td>
<td style="width:5%;"></td>
<td style="width:92%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td colspan="2" style="white-space:nowrap;vertical-align:bottom;text-align:center;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt;border-bottom:1pt solid #000000;display:inline-block">Exhibit <br />No. </p> </td>
<td style="white-space:nowrap;vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;display:inline-block;">&#160;</td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:left;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:8pt;margin-bottom:0pt;margin-top:0pt;border-bottom:1pt solid #000000;display:inline-block">Description </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">99.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d23206dex991.htm">2004 Employee Stock Purchase Plan, as amended </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">99.2 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d23206dex992.htm">Non-Employee Director Compensation Policy </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">104</p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Cover page Interactive Data File (embedded within the Inline XBRL document)</p> </td> </tr> </table> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">SIGNATURES </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:0px;margin-right:auto">
<tr>
<td style="width:47%;"></td>
<td style="width:1%;"></td>
<td style="width:4%;"></td>
<td></td>
<td style="width:47%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Date: June 29, 2020 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td colspan="3" style="vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">ACADIA Pharmaceuticals Inc. </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">By: </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;margin-bottom:1pt;font-size:10pt;margin-top:0pt;border-bottom:1px solid #000000">/s/ Austin D. Kim </p> </td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Name: </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Austin D. Kim </p> </td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Title: </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Executive Vice President, General Counsel&#160;&#038; Secretary </p> </td> </tr> </table> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>
 </body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d23206dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ACADIA PHARMACEUTICALS INC. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2004 EMPLOYEE STOCK PURCHASE PLAN
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ADOPTED BY THE BOARD OF DIRECTORS ON FEBRUARY&nbsp;25, 2004 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>APPROVED BY STOCKHOLDERS ON MAY&nbsp;5, 2004 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>AMENDED BY THE BOARD OF DIRECTORS ON APRIL&nbsp;29, 2016 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>APPROVED BY
STOCKHOLDERS ON JUNE&nbsp;10, 2016 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMENDED BY THE BOARD OF DIRECTORS: APRIL&nbsp;27, 2019 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>APPROVED BY THE STOCKHOLDERS: JUNE&nbsp;26, 2019 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>AMENDED BY THE BOARD OF DIRECTORS: APRIL&nbsp;28, 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>APPROVED BY THE
STOCKHOLDERS: JUNE&nbsp;23, 2020 </B></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PURPOSE. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B>&nbsp;The purpose of the Plan is to provide a means by which Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of the Common
Stock of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B>&nbsp;The Company, by means of the Plan, seeks to retain the services of such Employees, to
secure and retain the services of new Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B>&nbsp;The Company intends that the Purchase Rights be considered options issued under an Employee Stock Purchase Plan.
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DEFINITIONS. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As used in the Plan and any Offering, unless otherwise specified, the following terms have the meanings set forth below: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B><B><I>&nbsp;&#147;Annual Meeting&#148;</I></B><B><I></I></B>&nbsp;means the annual meeting of the stockholders of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B><B><I>&nbsp;&#147;Board&#148;</I></B><I></I>&nbsp;means the Board of Directors of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B><B><I>&nbsp;&#147;Code&#148;</I></B><I></I>&nbsp;means the Internal Revenue Code of 1986, as amended<I>.</I> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B><B><I>&nbsp;&#147;Committee&#148;</I></B><I></I>&nbsp;means a committee appointed by the Board in accordance with
Section&nbsp;3(c) of the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e)</B><B><I>&nbsp;&#147;Common Stock&#148;</I></B>&nbsp;means the common stock of the
Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(f)</B><B><I>&nbsp;&#147;Company&#148;</I></B>&nbsp;means ACADIA Pharmaceuticals Inc., a Delaware corporation.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(g)</B><B><I>&nbsp;&#147;Contributions&#148;</I></B>&nbsp;means the payroll deductions and other additional payments that
a Participant contributes to fund the exercise of a Purchase Right. A Participant may make payments not through payroll deductions only if specifically provided for in the Offering, and then only if the Participant has not already had the maximum
permitted amount withheld through payroll deductions during the Offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(h)</B><B><I>&nbsp;&#147;Corporate
Transaction&#148;</I></B>&nbsp;means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events: </FONT></P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:9%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B>&nbsp;a sale, exchange, lease, license or other disposition of all or
substantially all of the consolidated assets of the Company; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:9%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B>&nbsp;a sale, exchange or other disposition of more
than fifty percent (50%) of the outstanding securities of the Company; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:9%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B>&nbsp;a merger, consolidation or similar
transaction following which the Company is not the surviving corporation; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:9%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)</B>&nbsp;a merger, consolidation or
similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger,
consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B><B><I>&nbsp;&#147;Director&#148;</I></B><I></I>&nbsp;means a member of the Board. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(j)</B><B><I>&nbsp;&#147;Eligible Employee&#148;</I></B><I></I>&nbsp;means an Employee who meets the requirements set forth in the
Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(k)</B><B><I>&nbsp;&#147;Employee&#148;</I></B><I></I>&nbsp;means any person, including Officers and Directors, who is employed for purposes of Section&nbsp;423(b)(4) of the Code by the Company or a
Related Corporation. Neither service as a Director nor payment of a director&#146;s fee shall be sufficient to make an individual an Employee of the Company or a Related Corporation. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(l)</B><B><I>&nbsp;&#147;Employee Stock Purchase Plan&#148;</I></B><I></I>&nbsp;means a plan that grants Purchase Rights intended to
be options issued under an &#147;employee stock purchase plan,&#148; as that term is defined in Section&nbsp;423(b) of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(m)</B><B><I>&nbsp;&#147;Exchange Act&#148;</I></B><I></I>&nbsp;means the Securities Exchange Act of 1934, as amended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(n)</B><B><I>&nbsp;&#147;Fair Market Value&#148;</I></B><I></I>&nbsp;means the value of a security, as determined in good faith by the Board. If the security is listed on any established stock exchange
or traded on the Nasdaq National Market or the Nasdaq SmallCap Market, the Fair Market Value of the security, unless otherwise determined by the Board,<I></I>&nbsp;shall be the closing sales price (rounded up where necessary to the nearest whole
cent) for such security (or the closing bid, if no sales were reported) as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the relevant security of the Company) on the Trading Day prior to the
relevant determination date, as reported in<I>&nbsp;The Wall Street Journal</I>&nbsp;or such other source as the Board deems reliable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(o)</B><B><I>&nbsp;&#147;IPO Date&#148;</I></B>&nbsp;means the effective date of the initial public offering of the Common Stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(p)</B><B><I>&nbsp;&#147;Offering&#148;</I></B><I></I>&nbsp;means the grant of Purchase Rights to purchase shares of Common Stock
under the Plan to Eligible Employees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(q)</B><B><I>&nbsp;&#147;Offering Date&#148;</I></B>&nbsp;means a date selected by
the Board for an Offering to commence. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(r) &#147;</B><B><I>Officer</I></B><B>&#148;</B><B></B>&nbsp;means<B></B>&nbsp;a
person who is an officer of the Company within the meaning of Section&nbsp;16 of the Exchange Act and the rules and regulations promulgated thereunder. </FONT></P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(s)</B><B><I>&nbsp;&#147;Participant&#148;</I></B><I></I>&nbsp;means an Eligible Employee
who holds&nbsp;an outstanding Purchase Right granted pursuant to the Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(t)</B><B><I>&nbsp;&#147;Plan&#148;</I></B><I></I>&nbsp;means this ACADIA Pharmaceuticals Inc. 2004 Employee Stock Purchase Plan.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(u)</B><B><I>&nbsp;&#147;Purchase Date&#148;</I></B><I></I>&nbsp;means one or more dates during an Offering established by
the Board on which Purchase Rights shall be exercised and as of which purchases of shares of Common Stock shall be carried out in accordance with such Offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(v)</B><B><I>&nbsp;&#147;Purchase Period&#148;</I></B>&nbsp;means a period of time specified within an Offering beginning on the Offering Date or on the next day following a Purchase Date within an
Offering and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(w)</B><B><I>&nbsp;&#147;Purchase Right&#148;</I></B><I></I>&nbsp;means an option to purchase shares of Common Stock granted pursuant
to the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(x)</B><B><I>&nbsp;&#147;Related Corporation&#148;</I></B><I></I>&nbsp;means any parent corporation or
subsidiary corporation, whether now or hereafter existing, as those terms are defined in Sections 424(e) and (f), respectively, of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(y)</B><B><I>&nbsp;&#147;Securities Act&#148;</I></B><I></I>&nbsp;means the Securities Act of 1933, as amended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(z) &#147;</B><B><I>Trading Day</I></B><B>&#148;</B><B></B>&nbsp;means any day on which the exchange(s) or market(s) on which shares of Common Stock are listed, whether it be an established stock
exchange, the Nasdaq National Market, the Nasdaq SmallCap Market or otherwise, is open for trading. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ADMINISTRATION. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B>&nbsp;The Board shall administer the Plan unless and until the Board delegates administration to a Committee, as provided in Section&nbsp;3(c). Whether or not the Board has delegated
administration, the Board shall have the final power to determine all questions of policy and expediency that may arise in the administration of the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B>&nbsp;The Board (or the Committee) shall have the power, subject to, and within the limitations of, the express provisions of the Plan: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:9%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B>&nbsp;To determine when and how Purchase Rights to purchase shares of Common Stock shall be granted and the provisions of each
Offering of such Purchase Rights (which need not be identical). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:9%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B>&nbsp;To designate from time to time which Related
Corporations of the Company shall be eligible to participate in the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:9%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B>&nbsp;To construe and interpret the
Plan and Purchase Rights, and to establish, amend and revoke rules and regulations for the administration of the Plan. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the
extent it shall deem necessary or expedient to make the Plan fully effective. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:9%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)</B>&nbsp;To amend the Plan as provided
in Section&nbsp;15. </FONT></P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:9%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v)</B>&nbsp;Generally, to exercise such powers and to perform such acts as it deems
necessary or expedient to promote the best interests of the Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:9%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(vi)</B>&nbsp;To adopt such procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary&nbsp;or appropriate to
permit participation in the Plan by Employees who are foreign nationals or employed outside the United States. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B>&nbsp;The Board may delegate administration of the Plan to a Committee of the Board composed of one (1)&nbsp;or more members of
the Board. If administration is delegated to a Committee, the Committee shall have, in connection with the administration of the Plan, the powers theretofore possessed by the Board, subject, however, to such resolutions, not inconsistent with the
provisions of the Plan, as may be adopted from time to time by the Board. The Board may abolish the Committee at any time and revest in the Board the administration of the Plan. If administration is delegated to a Committee, references to the Board
in this Plan and in the Offering document shall thereafter be deemed to be to the Board or the Committee, as the case may be. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B>&nbsp;All determinations, interpretations and constructions made by the Board in good faith shall not be subject to review by
any person and shall be final, binding and conclusive on all persons. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SHARES OF COMMON STOCK SUBJECT TO THE PLAN. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B>&nbsp;Subject to the provisions of Section&nbsp;14 relating to adjustments upon changes in stock after the IPO Date, the shares of Common Stock that may be sold pursuant to Purchase Rights shall
not exceed in the aggregate 5,525,000 shares of Common Stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B>&nbsp;The shares of Common Stock subject to the Plan
may be unissued shares or shares that have been bought on the open market at prevailing market prices or otherwise. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GRANT OF PURCHASE RIGHTS; OFFERING. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B>&nbsp;The Board may from time to time grant or provide for the grant of Purchase Rights to purchase shares of Common Stock under the Plan to Eligible Employees in an Offering (consisting of one
or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate, which shall comply with the requirement of
Section&nbsp;423(b)(5) of the Code that all Employees granted Purchase Rights shall have the same rights and privileges. The terms and conditions of an Offering shall be incorporated by reference into the Plan and treated as part of the Plan. The
provisions of separate Offerings need not be identical, but each Offering shall include (through incorporation of the provisions of this Plan by reference in the document comprising the Offering or otherwise) the period during which the Offering
shall be effective, which period shall not exceed twenty-seven (27)&nbsp;months beginning with the Offering Date, and the substance of the provisions contained in Sections 6 through 9, inclusive. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B>&nbsp;If a Participant has more than one Purchase Right outstanding under the Plan, unless he or she otherwise indicates in
agreements or notices delivered hereunder: (i)&nbsp;each agreement or notice delivered by that Participant shall be deemed to apply to all of his or her Purchase Rights under the Plan, and (ii)&nbsp;a Purchase Right with a lower exercise price (or
an earlier-granted Purchase Right, if different Purchase Rights have identical exercise prices) shall be exercised to the fullest possible extent before a Purchase Right with a higher exercise price (or a later-granted Purchase Right if different
Purchase Rights have identical exercise prices) shall be exercised. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ELIGIBILITY. </B></FONT></P></TD></TR></TABLE>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B>&nbsp;Purchase Rights may be granted only to Employees of the Company or, as the
Board may designate as provided in Section&nbsp;3(b), to Employees of a Related Corporation. Except as provided in Section&nbsp;6(b), an Employee shall not be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date, such
Employee has been in the employ of the Company or the Related Corporation, as the case may be, for such continuous period preceding such Offering Date as the Board may require, but in no event shall the required period of continuous employment be
greater than two (2)&nbsp;years. In addition, the Board may provide that no Employee shall be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date, such Employee&#146;s customary employment with the Company or the
Related Corporation is more than twenty (20)&nbsp;hours per week and more than five (5)&nbsp;months per calendar year. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B>&nbsp;The Board may provide that each person who, during the course of an Offering, first becomes an Eligible Employee shall,
on a date or dates specified&nbsp;in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter, receive a Purchase Right under that Offering, which Purchase Right shall thereafter be
deemed to be a part of that Offering. Such Purchase Right shall have the same characteristics as any Purchase Rights originally granted under that Offering, as described herein, except that: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:9%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B>&nbsp;the date on which such Purchase Right is granted shall be the &#147;Offering Date&#148; of such Purchase Right for all
purposes, including determination of the exercise price of such Purchase Right; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:9%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B>&nbsp;the period of the Offering
with respect to such Purchase Right shall begin on its Offering Date and end coincident with the end of such Offering; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:9%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B>&nbsp;the Board may provide that if such person first becomes an Eligible Employee within a specified period of time before
the end of the Offering, he or she shall not receive any Purchase Right under that Offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B>&nbsp;No Employee
shall be eligible for the grant of any Purchase Rights under the Plan if, immediately after any such Purchase Rights are granted, such Employee owns stock possessing five percent (5%) or more of the total combined voting power or value of all
classes of stock of the Company or of any Related Corporation. For purposes of this Section&nbsp;6(c), the rules of Section&nbsp;424(d) of the Code shall apply in determining the stock ownership of any Employee, and stock which such Employee may
purchase under all outstanding Purchase Rights and options shall be treated as stock owned by such Employee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B>&nbsp;As specified by Section&nbsp;423(b)(8) of the Code, an Eligible Employee may be granted Purchase Rights under the Plan
only if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such Eligible Employee&#146;s rights to purchase stock of the Company or any
Related Corporation to accrue at a rate which exceeds twenty five thousand dollars ($25,000) of Fair Market Value of such stock (determined at the time such rights are granted, and which, with respect to the Plan, shall be determined as of their
respective Offering Dates) for each calendar year in which such rights are outstanding at any time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e)</B>&nbsp;Officers
of the Company and any designated Related Corporation, if they are otherwise Eligible Employees, shall be eligible to participate in Offerings under the Plan. Notwithstanding the foregoing, the Board may provide in an Offering that Employees who are
highly compensated Employees within the meaning of Section&nbsp;423(b)(4)(D) of the Code shall not be eligible to participate. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PURCHASE RIGHTS; PURCHASE PRICE. </B></FONT></P></TD></TR></TABLE>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B>&nbsp;On each Offering Date, each Eligible Employee, pursuant to an Offering made
under the Plan, shall be granted a Purchase Right to purchase up to that number of shares of Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board, but in either case not exceeding fifteen
percent (15%), of such Employee&#146;s Earnings (as defined by the Board in each Offering) during the period that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated in the
Offering, which date shall be no later than the end of the Offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B>&nbsp;The Board shall establish one
(1)&nbsp;or more Purchase Dates during an Offering as of which Purchase Rights granted pursuant to that&nbsp;Offering shall be exercised and purchases of shares of Common Stock shall be carried out in accordance with such Offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B>&nbsp;In connection with each Offering made under the Plan, the Board may specify a maximum number of shares of Common Stock
that may be purchased by any Participant on any Purchase Date during such Offering. In connection with each Offering made under the Plan, the Board may specify a maximum aggregate number of shares of Common Stock that may be purchased by all
Participants pursuant to such Offering. In addition, in connection with each Offering that contains more than one Purchase Date, the Board may specify a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on
any Purchase Date under the Offering. If the aggregate purchase of shares of Common Stock issuable upon exercise of Purchase Rights granted under the Offering would exceed any such maximum aggregate number, then, in the absence of any Board action
otherwise, a pro rata allocation of the shares of Common Stock available shall be made in as nearly a uniform manner as shall be practicable and equitable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B>&nbsp;The purchase price of shares of Common Stock acquired pursuant to Purchase Rights shall be not less than the lesser of: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:9%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B>&nbsp;an amount equal to eighty-five percent (85%) of the Fair Market Value of the shares of Common Stock on the Offering Date;
or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:9%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B>&nbsp;an amount equal to eighty-five percent (85%) of the Fair Market Value of the shares of Common Stock on
the applicable Purchase Date. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PARTICIPATION; WITHDRAWAL; TERMINATION. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B>&nbsp;A Participant may elect to authorize payroll deductions pursuant to an Offering under the Plan by completing and delivering to the Company, within the time specified in the Offering, an
enrollment form (in such form as the Company may provide). Each such enrollment form shall authorize an amount of Contributions expressed as a percentage of the submitting Participant&#146;s Earnings (as defined in each Offering) during the Offering
(not to exceed the maximum percentage specified by the Board). Each Participant&#146;s Contributions shall remain the property of the Participant at all times prior to the purchase of Common Stock, but such Contributions may be commingled with the
assets of the Company and used for general corporate purposes except where applicable law requires that Contributions be deposited with an independent third party. To the extent provided in the Offering, a Participant may begin making Contributions
after the beginning of the Offering. To the extent provided in the Offering, a Participant may thereafter reduce (including to zero) or increase his or her Contributions. To the extent specifically provided in the Offering, in addition to making
Contributions by payroll deductions, a Participant may make Contributions through the payment by cash or check prior to each Purchase Date of the Offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B>&nbsp;During an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company a notice of withdrawal in such form as the Company may provide.
</FONT></P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Such withdrawal may be elected at any time prior to the end of the Offering, except as provided otherwise in the Offering. Upon such withdrawal from the Offering by a Participant, the Company
shall distribute to such Participant all of his or her accumulated Contributions (reduced to the extent, if any, such Contributions have been used to acquire shares of Common Stock for the Participant) under the Offering, and such Participant&#146;s
Purchase Right in that Offering shall thereupon terminate. A Participant&#146;s withdrawal from an Offering shall have no effect upon such Participant&#146;s eligibility to participate in any other Offerings under the Plan, but such Participant
shall be required to deliver a new enrollment form in order to participate in subsequent Offerings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B>&nbsp;Purchase
Rights granted pursuant to any Offering under the Plan shall terminate immediately upon a Participant ceasing to be an Employee for any reason or for no reason (subject to any post-employment participation&nbsp;period required by law) or other lack
of eligibility. The Company shall distribute to such terminated or otherwise ineligible Employee all of his or her accumulated Contributions (reduced to the extent, if any, such Contributions have been used to acquire&nbsp;shares of Common Stock for
the terminated or otherwise ineligible Employee) under the Offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B>&nbsp;Purchase Rights shall not be
transferable by a Participant otherwise than by will, the laws of descent and distribution, or a beneficiary designation as provided in Section&nbsp;13. During a Participant&#146;s lifetime, Purchase Rights shall be exercisable only by such
Participant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e)</B>&nbsp;Unless otherwise specified in an Offering, the Company shall have no obligation to pay interest
on Contributions, including, but not limited to, any amounts distributed to Participants pursuant to Sections 8(b), 8(c) and 9(b) hereof. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXERCISE; HOLDING RESTRICTIONS. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B>&nbsp;On each Purchase Date during an Offering, each Participant&#146;s accumulated Contributions shall be applied to the purchase of shares of Common Stock up to the maximum number of shares of
Common Stock permitted pursuant to the terms of the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares shall be issued upon the exercise of Purchase Rights unless specifically provided for in the
Offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B>&nbsp;If any amount of accumulated Contributions remains in a Participant&#146;s account after the
purchase of shares of Common Stock and such remaining amount is less than the amount required to purchase one share of Common Stock on the final Purchase Date of an Offering, then such remaining amount shall be held in such Participant&#146;s
account for the purchase of shares of Common Stock under the next Offering under the Plan, unless such Participant withdraws from such next Offering, as provided in Section&nbsp;8(b), or is not eligible to participate in such Offering, as provided
in Section&nbsp;6, in which case such amount shall be distributed to such Participant after the final Purchase Date, without interest. If the amount of Contributions remaining in a Participant&#146;s account after the purchase of shares of Common
Stock is at least equal to the amount required to purchase one (1)&nbsp;whole share of Common Stock on the final Purchase Date of the Offering, then such remaining amount shall be distributed in full to such Participant at the end of the Offering.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B>&nbsp;No Purchase Rights may be exercised to any extent unless the shares of Common Stock to be issued upon such
exercise under the Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all laws applicable to the Plan. If on a Purchase Date during any Offering hereunder the shares of
Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights or any Offering shall be exercised on such Purchase Date, and the Purchase Date shall be delayed until the shares of Common Stock are subject to such an
effective registration statement and the Plan is in such compliance, except that the Purchase Date shall not be </FONT></P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
delayed more than twelve (12)&nbsp;months and the Purchase Date shall in no event be more than twenty-seven (27)&nbsp;months from the Offering Date. If, on the Purchase Date under any Offering
hereunder, as delayed to the maximum extent permissible, the shares of Common Stock are not registered and the Plan is not in such compliance, no Purchase Rights or any Offering shall be exercised and all Contributions accumulated during the
Offering (reduced to the extent, if any, such Contributions have been used to acquire shares of Common Stock) shall be distributed to the Participants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B>&nbsp;With respect to any Common Stock of the Company purchased under any Offering, as a condition to participating in, and purchasing shares of Common Stock under this Plan, the Board may
require prior to the beginning of such Offering that each Participant must irrevocably agree that, without the prior written consent of the Company, such Participant will not, directly or indirectly, (1)&nbsp;offer for sale, sell, pledge, or
otherwise dispose of (or enter into any transaction or device that is designed to, or could&nbsp;be expected to, result in the disposition by any person at any time in the future of) any shares of Common Stock of the Company (the &#147;Held
Shares&#148;) purchased by such Participant in such Offering, or (2)&nbsp;enter into any swap or other derivatives transaction&nbsp;that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of the Held
Shares, in each case before the passage of a holding period determined by the Board which commences on the date the Participant purchased the applicable Held Shares (the &#147;Holding Period&#148;). The Company may impose stop-transfer instructions
with respect to the shares of Common Stock subject to the foregoing restriction until the end of the applicable Holding Period. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e)</B>&nbsp;Each Participant understands and agrees that on any certificates evidencing&nbsp;the shares of Common Stock purchased
under the Plan, the Company may place a legend, substantially in the form of the following: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:9%"><FONT STYLE="font-family:Times New Roman" SIZE="2">THE SHARES EVIDENCED BY THIS
CERTIFICATE CANNOT BE SOLD UNTIL [INSERT DATE THAT IS EQUAL TO THE HOLDING PERIOD AFTER THE DATE OF PURCHASE]. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>COVENANTS OF THE COMPANY. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company shall seek to obtain from each federal, state, foreign or other regulatory commission or agency having jurisdiction over the Plan such authority as may be required to issue and sell shares of
Common Stock upon exercise of the Purchase Rights. If, after commercially reasonable efforts, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful
issuance and sale of shares of Common Stock under the Plan, the Company shall be relieved from any liability for failure to issue and sell shares of Common Stock upon exercise of such Purchase Rights unless and until such authority is obtained.
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>USE OF PROCEEDS FROM SHARES OF COMMON STOCK. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights shall constitute general funds of the Company. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RIGHTS AS A STOCKHOLDER. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A Participant shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of Common Stock subject to Purchase Rights unless and until the Participant&#146;s
shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent). </FONT></P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DESIGNATION OF BENEFICIARY. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B>&nbsp;A Participant may file a written designation of a beneficiary who is to receive any shares of Common Stock and/or cash, if any, from the Participant&#146;s account under the Plan in the
event of such Participant&#146;s death subsequent to the end of an Offering but prior to delivery to the Participant of such shares of Common Stock or cash. In addition, a Participant may file a written designation of a beneficiary who is to receive
any cash from the Participant&#146;s account under the Plan in the event of such Participant&#146;s death during an Offering. Any such designation shall be on a form provided by or otherwise acceptable to the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B>&nbsp;The Participant may change such designation of beneficiary at any time by written notice to the Company. In the event of
the death of a Participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such Participant&#146;s death, the Company shall deliver such shares of Common Stock and/or cash to the executor or
administrator of the estate of the Participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its sole discretion, may deliver such shares of Common Stock and/or cash to the spouse or
to any one or more dependents or relatives of the Participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ADJUSTMENTS UPON CHANGES IN SECURITIES; CORPORATE TRANSACTIONS. </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B>&nbsp;If, after the IPO Date, any change is made in the shares of Common Stock, subject to the Plan, or subject to any Purchase
Right, without the receipt of consideration by the Company (through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of
shares, exchange of shares, change in corporate structure or other transaction not involving the receipt of consideration by the Company), the Plan shall be appropriately adjusted in the type(s), class(es) and maximum number of shares of Common
Stock subject to the Plan pursuant to Section&nbsp;4(a), and the outstanding Purchase Rights shall be appropriately adjusted in the type(s), class(es), number of shares and purchase limits of such outstanding Purchase Rights. The Board shall make
such adjustments, and its determination shall be final, binding and conclusive. (The conversion of any convertible securities of the Company shall not be treated as a &#147;transaction not involving the receipt of consideration by the
Company.&#148;) </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B>&nbsp;In the event of a Corporate Transaction, then: (i)&nbsp;any surviving or acquiring
corporation may continue or assume Purchase Rights outstanding under the Plan or may substitute similar rights (including a right to acquire the same consideration paid to stockholders in the Corporate Transaction) for those outstanding under the
Plan, or (ii)&nbsp;if any surviving or acquiring corporation does not continue or assume such Purchase Rights or does not substitute similar rights for Purchase Rights outstanding under the Plan, then, the Participants&#146; accumulated
Contributions shall be used to purchase shares of Common Stock within ten (10)&nbsp;business days prior to the Corporate Transaction under the ongoing Offering, and the Participants&#146; Purchase Rights under the ongoing Offering shall terminate
immediately after such purchase. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMENDMENT OF THE PLAN. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B>&nbsp;The Board at any time, and from time to time, may amend the Plan. However, except as provided in Section&nbsp;14 relating to adjustments upon changes in securities and except as to
amendments solely to benefit the administration of the Plan, to take account of a change in legislation or to obtain or maintain favorable tax, exchange control or regulatory treatment for Participants or the Company or any Related Corporation, no
amendment shall be effective unless approved by the stockholders of the </FONT></P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Company to the extent stockholder approval is necessary for the Plan to satisfy the requirements of Section&nbsp;423 of the Code or other applicable laws or regulations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B>&nbsp;It is expressly contemplated that the Board may amend the Plan in any respect the Board deems necessary or advisable to
provide Employees with the maximum benefits provided or to be provided under the provisions of the Code and the regulations promulgated thereunder relating to Employee Stock Purchase Plans or to bring the Plan and/or Purchase Rights into compliance
therewith. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B>&nbsp;The rights and obligations under any Purchase Rights granted before amendment of the Plan shall
not be impaired by any amendment of the Plan except: (i)&nbsp;with the consent of the person to whom such Purchase Rights were granted, or (ii)&nbsp;as necessary to comply with any laws or governmental regulations (including, without limitation, the
provisions of the Code and the regulations promulgated thereunder relating to Employee Stock Purchase Plans). </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TERMINATION OR SUSPENSION OF THE PLAN. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B>&nbsp;The Board in its discretion may suspend or terminate the Plan at any time. Unless sooner terminated, the Plan shall terminate at the time that all of the shares of Common Stock reserved
for issuance under the Plan, as increased and/or adjusted from time to time, have been issued under the terms of the Plan. No Purchase Rights may be granted under the Plan while the Plan is suspended or after it is terminated. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B>&nbsp;Any benefits, privileges, entitlements and obligations under any Purchase Rights while the Plan is in effect shall not be
impaired by suspension or termination of the Plan except (i)&nbsp;as expressly provided in the Plan or with the consent of the person to whom such Purchase Rights were granted, (ii)&nbsp;as necessary to comply with any laws, regulations, or listing
requirements, or (iii)&nbsp;as necessary to ensure that the Plan and/or Purchase Rights comply with the requirements of Section&nbsp;423 of the Code. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>17.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EFFECTIVE DATE OF PLAN. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Plan shall become effective as determined by the Board, but no Purchase Rights shall be exercised unless and until the Plan has been approved by the stockholders of the Company within twelve
(12)&nbsp;months before or after the date the Plan is adopted by the Board. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>18.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MISCELLANEOUS PROVISIONS. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B>&nbsp;The Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering shall in any way alter the at will nature of a Participant&#146;s employment or be
deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a Related Corporation, or on the part of the Company or a Related Corporation to continue the employment of a
Participant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B>&nbsp;The provisions of the Plan shall be governed by the laws of the State of
California<B></B>&nbsp;without resort to that state&#146;s conflicts of laws rules. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d23206dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ACADIA P<SMALL>HARMACEUTICALS</SMALL> I<SMALL>NC</SMALL>. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N<SMALL>ON</SMALL><FONT STYLE="white-space:nowrap">-E</FONT><SMALL>MPLOYEE</SMALL> D<SMALL>IRECTOR</SMALL> C<SMALL>OMPENSATION</SMALL>
P<SMALL>OLICY</SMALL> </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each member of the Board of Directors (the &#147;<B><I>Board</I></B>&#148;) of ACADIA Pharmaceuticals Inc. (the
&#147;<B><I>Company</I></B>&#148;) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, a &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</I></B>&#148;) will, automatically and
without further action by the Board or the Compensation Committee of the Board (the &#147;<B><I>Compensation Committee</I></B>&#148;), receive the compensation described in this <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director
Compensation Policy (this &#147;<B><I>Policy</I></B>&#148;). A <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash is to be
paid or equity awards are to be granted, as the case may be.&nbsp;This Policy may be amended at any time in the sole discretion of the Board, or by the Compensation Committee at the recommendation of the Board. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Annual Cash Retainer </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director will automatically, and without further action by the Board or
Compensation Committee, receive cash compensation solely in the form of annual retainers, as set forth in the table below.&nbsp;The annual retainer amounts are payable immediately following the first meeting of the Board that follows the annual
meeting of the Company&#146;s stockholders. The annual retainer amount will be <FONT STYLE="white-space:nowrap">pro-rated</FONT> for a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director who joins the Board other than at the first meeting
of the Board following the annual meeting of stockholders. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annual Retainer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional Retainer for Board Chair</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional Retainer for Audit Committee Chair</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional Retainer for Audit Committee Member <FONT STYLE="white-space:nowrap">(non-Chair)</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional Retainer for Compensation Committee Chair</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional Retainer for Compensation Committee Member <FONT STYLE="white-space:nowrap">(non-Chair)</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional Retainer for Nominating and Corporate Governance Committee Chair</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional Retainer for Nominating and Corporate Governance Committee Member
<FONT STYLE="white-space:nowrap">(non-Chair)</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Equity Compensation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The equity compensation set forth below will be granted under the Company&#146;s 2010 Equity Incentive Plan, as amended (the &#147;<B><I>Plan</I></B>&#148;). All stock options granted under this Policy
will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying common stock on the date of grant,&nbsp;and a term of 10 years from the date of grant (subject to
earlier termination in connection with a termination of service as provided in the stock option agreement). </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Initial Grant</U>: For each <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director who is first elected or appointed to the Board,
on the date of such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director&#146;s initial election or appointment to the Board (or, if such date is not a market trading day, the first market trading day thereafter), the <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director will be automatically, and without further action by the Board or Compensation Committee, granted the following two equity awards with an aggregate fair value of $300,000: (i) a stock option to
purchase shares of the Company&#146;s common stock with a fair value of $150,000 and (ii)&nbsp;a restricted stock unit award with a fair value of $150,000 (calculating the value of such equity awards based on the grant date fair value thereof for
financial reporting purposes). The shares subject to each such stock option and </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the restricted stock units will vest in equal annual installments over two years following the date of grant, subject to the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director&#146;s
Continuous Service (as defined in the Plan) on each such vesting date. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Annual Grant</U>: At the first Board meeting following each annual meeting of stockholders of the Company, each <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director who continues to serve as a member of the Board following such stockholders meeting will be automatically, and without further action by the Board or Compensation Committee, granted the
following two equity awards with an aggregate fair value of $300,000: (i)&nbsp;a stock option to purchase&nbsp;shares of the Company&#146;s common stock with a fair value of $150,000&nbsp;and (ii)&nbsp;a restricted stock unit award with a fair value
of $150,000&nbsp;(calculating the value of such&nbsp;equity awards&nbsp;based on the grant date fair value&nbsp;thereof for financial reporting purposes). The shares subject to each such stock option will vest quarterly over one year following the
date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date,&nbsp;and the restricted stock units will vest in full upon the earlier of one year following the date of grant or
the next annual meeting date, in each case&nbsp;subject to the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director&#146;s Continuous Service (as defined in the Plan) on each such vesting date.&nbsp;A new
<FONT STYLE="white-space:nowrap">non-employee&nbsp;director</FONT> who joins&nbsp;the Board other than&nbsp;at the&nbsp;first Board meeting following&nbsp;the annual meeting&nbsp;of stockholders may&nbsp;be granted an annual award that is prorated
for the portion of the year remaining until the next annual meeting&nbsp;of stockholders. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Reimbursement of Expenses
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon presentation of documentation of such expenses reasonably satisfactory to the Company, each <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director is entitled to be reimbursed for reasonable travel and other expenses incurred in connection with attending meetings of the Board and any Committee of the Board on which he or she serves.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Additional Requirements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In making any future changes to compensation payable to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors, the Board or Compensation Committee will evaluate the practices of the peer group of
companies that serve as references for executive compensation benchmarking, as well as then current general best practices regarding director compensation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee will review this Policy on at least a biennial basis and engage an independent compensation consultant to assist in such review. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore, the Company will not permit compensation to be paid to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors for
their service as such other than as provided for in this Policy, unless there are extraordinary circumstances as determined by the Compensation Committee or the Board.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All payments to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors will be disclosed in accordance with applicable law, regulations and exchange or national market system requirements.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Approved by the Board of Directors: April&nbsp;28, 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Effective: April&nbsp;28, 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Approved by the Stockholders: June&nbsp;23, 2020
</B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>acad-20200623.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-4 Build:20200505.2 -->
<!-- Creation date: 6/29/2020 11:59:08 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:acad="http://www.acadia-pharm.com/20200623"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.acadia-pharm.com/20200623"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acad-20200623_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acad-20200623_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>acad-20200623_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-4 Build:20200505.2 -->
<!-- Creation date: 6/29/2020 11:59:08 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>acad-20200623_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-4 Build:20200505.2 -->
<!-- Creation date: 6/29/2020 11:59:08 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="acad-20200623.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>d23206d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="acad-20200623.xsd" xlink:type="simple"/>
    <context id="duration_2020-06-23_to_2020-06-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070494</identifier>
        </entity>
        <period>
            <startDate>2020-06-23</startDate>
            <endDate>2020-06-23</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2020-06-23_to_2020-06-23"
      id="Hidden_dei_EntityRegistrantName">ACADIA PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2020-06-23_to_2020-06-23">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2020-06-23_to_2020-06-23"
      id="Hidden_dei_EntityCentralIndexKey">0001070494</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2020-06-23_to_2020-06-23">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2020-06-23_to_2020-06-23">2020-06-23</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2020-06-23_to_2020-06-23">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2020-06-23_to_2020-06-23">000-50768</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2020-06-23_to_2020-06-23">06-1376651</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2020-06-23_to_2020-06-23">3611 Valley Centre Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2020-06-23_to_2020-06-23">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2020-06-23_to_2020-06-23">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2020-06-23_to_2020-06-23">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2020-06-23_to_2020-06-23">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2020-06-23_to_2020-06-23">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2020-06-23_to_2020-06-23">558-2871</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2020-06-23_to_2020-06-23">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2020-06-23_to_2020-06-23">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2020-06-23_to_2020-06-23">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2020-06-23_to_2020-06-23">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2020-06-23_to_2020-06-23">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2020-06-23_to_2020-06-23">ACAD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2020-06-23_to_2020-06-23">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2020-06-23_to_2020-06-23">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140525363397864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ACADIA PHARMACEUTICALS INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 23,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1376651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3611 Valley Centre Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">558-2871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACAD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M BHL""H+.P^^=I)*TM W.Y4QV:^W.YW;N RH#Z(ODSJGJD^=OD[6XR3AJ0-
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M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ SX#=4&60>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
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M+GAM;%!+ 0(4 Q0    ( ,^ W5"4<VIT[@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( ,^ W5"97)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ SX#=4)").716!   \1   !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ,^ W5"#J:4#U $
M #(&   -              "  9D,  !X;"]S='EL97,N>&UL4$L! A0#%
M  @ SX#=4)>*NQS     $P(   L              ( !F X  %]R96QS+RYR
M96QS4$L! A0#%     @ SX#=4!PX9>H_ 0  / (   \              ( !
M@0\  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,^ W5 D'INBK0   /@!
M   :              "  >T0  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<U!+ 0(4 Q0    ( ,^ W5!ED'F2&0$  ,\#   3              "  =(1
K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  !P3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d23206d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d23206d8k.htm">d23206d8k.htm</File>
    <File>acad-20200623.xsd</File>
    <File>acad-20200623_lab.xml</File>
    <File>acad-20200623_pre.xml</File>
    <File>d23206dex991.htm</File>
    <File>d23206dex992.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d23206d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d23206d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "acad-20200623_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "acad-20200623_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "acad-20200623.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "acad",
   "nsuri": "http://www.acadia-pharm.com/20200623",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d23206d8k.htm",
      "contextRef": "duration_2020-06-23_to_2020-06-23",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d23206d8k.htm",
      "contextRef": "duration_2020-06-23_to_2020-06-23",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-20-182326-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-20-182326-xbrl.zip
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M.\ID<Y:;F^[,UU?USL&?_P)02P,$%     @ SX#=4"SB/@6(!@  2D<  !4
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MKB@C@WI#811H=2"J+/$#@<T'H504=P@R_3?Y >A*<,.P=C;.;!@&X!E>7 [
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M.3$N:'1M[7U9<]M(MN:[(O0?$+[3-Z0(6F5Y:V_E"%JB2^PK2QJ2KKHU$_,
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MDU  *V&>57 ';ON92*)5(XVJG.P#:RS;WRJS5MYA#H=M/<J!2T(6:"N9*)N
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MF%@=/1*HL#2^@U5*0VY+4QG("[<,A&06/LL05.&TS>DK&@<O0ECVG'_"B<
M;V*PL]%O1&YIG")5 3?23,6[F<K:+N=2-0,D(;Q@4 /T@VNXGN^V% (NPX55
MKRV:X>,.E?B)AD7E@ASP$54QN!FNY8#XSI+R'KSIT+7:>\ ES./"KR-WU, A
M/YY37V0JD@GLJEOV]PQ*K(!!Q2[R7F-S2PU>WL(8EH\+++P.#I[^7;K L /+
M66$ET&@.<S:&+KP/9$'Q1#300O*]EX?P,E"T?"T+G@H?R-QF\QBF0Y_:&WA]
M!$B24"$QP@9>AJ"=/.A*+UUL,!-L,@BK[  ]F0F)FA@,C1#L*5D/QQ$^,@S
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MS%G,[^]QQ5O.JKV\S< >DHIL"4H)C-I^JALG=;RQ**>']&N:^6OV ]?+:0*
MY=:3JH MAA$^:W[:?G-7K;'@&P%S8^.PA0BT>"*),<NJG%8LN!7B"ZE\<_44
M 5AP,1PS$J\%-2;2*,P#I.6.67FC]J4DJ\K4"77LED\3)(3P/!K@[S@OD*'
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M^*%3[/S=DZ:7M6*LP@$(.>Q<7_#)Z0\?@052.R=$/0^$9@OJS@F%(0C8XEY
M[_#-T,B>7K &:'?!O8-+E),K:&'4XY+L>JH-F\"0&>0_RO<L?D7]7-\3HMW,
MU#S_4A5._J'B@8O1#@ZKY*!V4'N<;WHP4?OT!][MX1 #@%OVK4A:5W@WF?#U
MB/P[$G&,?O#6D3@?-OZ]4]P'\REN8/#J[ LTV/^UP?\!4$L! A0#%     @
MSX#=4".SE>]F P  ,PP  !$              ( !     &%C860M,C R,# V
M,C,N>'-D4$L! A0#%     @ SX#=4"SB/@6(!@  2D<  !4
M ( !E0,  &%C860M,C R,# V,C-?;&%B+GAM;%!+ 0(4 Q0    ( ,^ W5!!
M#AJMT 0  -@L   5              "  5 *  !A8V%D+3(P,C P-C(S7W!R
M92YX;6Q02P$"% ,4    " #/@-U0,/)JLS84  !3P@  #0
M@ %3#P  9#(S,C V9#AK+FAT;5!+ 0(4 Q0    ( ,^ W5"YMCP:9BL  $3D
M   0              "  ;0C  !D,C,R,#9D97@Y.3$N:'1M4$L! A0#%
M  @ SX#=4.QZMF- #   X4   !               ( !2$\  &0R,S(P-F1E
>>#DY,BYH=&U02P4&      8 !@!\ 0  MEL

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
